---
title: Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon
nct_id: NCT07145008
overall_status: RECRUITING
phase: EARLY_PHASE1
sponsor: University of Baghdad
study_type: INTERVENTIONAL
primary_condition: Macular Edema (ME)
countries: Iraq
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07145008.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07145008"
ct_last_update_post_date: 2025-08-28
last_seen_at: "2026-05-12T06:47:52.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon

**NCT ID:** [NCT07145008](https://clinicaltrials.gov/study/NCT07145008)

## Key Facts

- **Status:** RECRUITING
- **Phase:** EARLY_PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 20
- **Lead Sponsor:** University of Baghdad
- **Conditions:** Macular Edema (ME), Non Infectious Uveitis
- **Start Date:** 2024-09-01
- **Completion Date:** 2026-12-01
- **CT.gov Last Update:** 2025-08-28

## Brief Summary

The goal of this study is to learn if a suprachoroidal triamcinolone injection can treat vision-threatening swelling in the center of the retina (macular edema) caused by non-infectious uveitis, especially in people who did not improve after a standard steroid injection around the eye (sub-Tenon injection).

The main questions it aims to answer are:

Does vision improve on the eye chart after the injection?

Does the injection lower retinal swelling (reduction in thickness) within 3 months?

Participants will:

Have a pre-treatment check (vision test, slit-lamp exam, and a retinal scan called OCT).

Receive one suprachoroidal triamcinolone injection under anesthetics drops in a sterile setting (operating room) with standard monitoring.

Return for visits about 1 month and 3 months after treatment for repeat vision tests, and OCT scans.

Contact the clinic if they notice pain, redness, new floaters, or worsening vision.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Non-infectious uveitis complicated with macular edema
* Uveitic macular edema of less than four months' duration
* Macular edema persisted despite lack of intra-ocular inflammation
* No response to posterior sub-Tenon triamcinolone acetonide injections

Exclusion Criteria:

* Those with epiretinal membrane-associated macular edema
* Below 18 years
```

## Arms

- **Suprachoroidal Triamcinolone treatment arm** (EXPERIMENTAL)

## Interventions

- **Suprachoroidal triamcinolone acetonide injection** (DRUG) — For suprachoroidal injection, we developed a custom-made delivery system to access the potential suprachoroidal space. A 1 mL tuberculin syringe fitted with a 27-gauge needle was prepared, and a plastic sleeve from a 24-26 G IV cannula was placed over the needle as a spacer to control penetration depth.

## Primary Outcomes

- **Visual acuity improvement** _(time frame: 3 months)_ — visual acuity improvement was defined as a gain of two or more lines in visual acuity or a reduction in logMAR values

## Secondary Outcomes

- **Central Macular Thickness** _(time frame: 3 Months)_

## Locations (1)

- Ibn Al-Haitham Eye Teaching Hospital, Baghdad, Iraq — _RECRUITING_

## Recent Field Changes (last 30 days)

- `outcomes.secondary` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.ibn al-haitham eye teaching hospital|baghdad||iraq` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07145008.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07145008*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*